← board
OKUR
OnKure, Inc.distress 6/10 · elevated risk$4.26-1%today-19% from 52w high
Oncology 2
Lead: HR+ and HER2+ advanced breast cancer · target HER2 · est. market ~$35B (approx, global)
Revenue
pre-revenue
Liquidity
$208M
Runway
4.1 yrs
Shares 1y
+195%
Price & events
+39.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
+3.9%
1W
+1.4%
1M
-13.1%
3M
+45.4%
6M
+79.0%
1Y
-71.6%
2Y
-95.3%
5Y
-97.2%
All
Overview
- Market Cap
- $172.08M
- Volume
- 6.70K
- 52 Week Range
- $2.00 – $5.27
- Total Shares
- 40.40M
- Float Shares
- 17.60M
- Short %
- 2.42%
- % Held by Insiders
- 10.48%
- % Held by Institutions
- 76.21%
- RVOL
- 0.02x
Pipeline stages · 1 programs
OKI-219, Fulvestrant, Trastuzumab, Tucatinib, AtirmociclibHER2
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-06-01 | Phase 1 | OKI-219, Fulvestrant, Trastuzumab, Tucatinib, Atirmociclib | Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation | 200 | recruiting |
| 2025-01-29 | Phase 1/2 | OKI-179 + binimetinib | RAS Mutation, NRAS Gene Mutation, Melanoma | 36 | completed |
Catalyst news & presentations · 4
- first half of 2027Guided 55%regulatory submissionFiled (NDA/BLA)OKI-345 · IND submission for PI3Kα pan-mutant-selective inhibitorSEC 8-K
- 2026Guided 40%readoutPhase 2OKI-219 · Phase 2 dose evaluation in OKI-219 + tucatinib and trastuzumab triplet and OKI-219 + ribociclib and fulvestrant triplet will be completedSEC 8-K
- as of March 26, 2026enrollment completesecondaryPhase 1OKI-219 · Completed enrollment in single-agent OKI-219 dose escalation (n=38) and OKI-219 + fulvestrant dose escalation (n=33)SEC 8-K
- 2H 2025readoutPhase 1OKI-219 · Data update for PI3KaH1047R mutant-selective inhibitor in Phase 1 trialSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $21 (+393% upside) · 4 analysts
- 2026-07-20HC Wainwright & Co.Buy
- 2026-03-16HC Wainwright & Co.Buy
- 2025-08-26HC Wainwright & Co.Buy
- 2025-03-18HC Wainwright & Co.Buy
- 2025-03-11OppenheimerOutperform
- 2025-01-28Jones TradingBuy
Competitors — HER2
Recent news
- 2026-07-22Price to sales forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
- 2026-07-21H.C. Wainwright cuts OnKure stock price target to $21 on valuation changes - Investing.com
- 2026-07-21OKUR Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
- 2026-07-20OKUR Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
- 2026-07-19OnKure Therapeutics (OKUR) price target decreased by 15.13% to 20.60 - MSN
- 2026-07-17JonesTrading Maintains OnKure Therapeutics(OKUR.US) With Hold Rating - Moomoo
- 2026-07-15Enterprise value to revenue forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
- 2026-07-15OnKure Therapeutics Spotlights Allosteric PI3Kα Drugs as 2027 IND Targets Near - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.